Collegium Pharmaceutical, Inc. (COLL) fundamentals score
Its mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium Pharmaceutical has developed, licensed, and acquired a portfolio of meaningfully differentiated products for use in the treatment of attention deficit hyperactivity disorder (“ADHD”) and moderate to severe pain.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 7.1 out of 10, Mixed fundamentals
- Growth: 5.6/10
- Profitability: 8.6/10
- Financial health: 5.2/10
- Earnings quality: 8.4/10
- Valuation: 8.1/10
Scores are calculated from Collegium Pharmaceutical, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10